Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data.

Authors :: Paules CI
Gallagher SK
Rapaka RR
Davey RT
Doernberg SB
Grossberg R
Hynes NA
Ponce PO
Short WR
Voell J
Wang J
Yang OO
Wolfe CR
Lye DC
Dodd LE
Benson CA
Source :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Apr 09; Vol. 74 (7), pp. 1260-1264.
Publication Year :: 2022
Abstract: This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.<br /> (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)

Subjects :: Adenosine Monophosphate analogs & derivatives
Alanine analogs & derivatives
Antiviral Agents therapeutic use
Clinical Trials as Topic
Humans
Respiration, Artificial
SARS-CoV-2
COVID-19 Drug Treatment

Language :: English
ISSN :: 1537-6591
Volume :: 74
Issue :: 7
Database :: MEDLINE
Journal :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publication Type :: Academic Journal
Accession number :: 34379740
Full Text :: https://doi.org/10.1093/cid/ciab695

Full Text Access

Tools